Tag: Zymfentra

Zymfentra (infliximab-dyyb), the first and only FDA-approved subcutaneous infliximab, was approved by the FDA in October 2023. Yes, **is Zymfentra available in the USA**, having become commercially available nationwide in March 2024.

Infliximab products are a cornerstone in treating inflammatory bowel disease, with over 60% of Crohn's disease patients on Zymfentra achieving remission in one study [1.6.5]. So, is Zymfentra the same as Remicade? While they share an active ingredient, their administration and approved uses differ significantly.

While initial clinical trial data didn't list fatigue as one of the most common adverse reactions, it has been reported by patients taking Zymfentra and other infliximab products during postmarketing surveillance. This feeling of unusual tiredness can stem from the medication itself, the underlying inflammatory bowel disease (IBD) it treats, or as a sign of a more serious complication.

With a wholesale acquisition cost (WAC) reported around $6,181 for a four-week supply, Zymfentra is a high-cost biologic medication used for inflammatory bowel disease. Understanding **how much does Zymfentra cost**, however, requires looking beyond this list price to consider factors like insurance coverage, discount cards, and patient assistance programs.

Approved by the FDA in October 2023, Zymfentra is the first and only subcutaneous formulation of infliximab available for maintenance treatment of inflammatory bowel disease (IBD). This innovative medication offers a new pathway for adult patients with moderate to severe Crohn’s disease or ulcerative colitis, providing a convenient, at-home option for long-term therapy.